Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded. As of April 2, 2026, the State Street SPDR S&P Biotech ETF (NYSE:XBI) ...
The biotech industry has been a robust roller-coaster over the last half decade. The State Street SPDR S&P Biotech ETF (NYSE: ...
The iShares Biotechnology ETF is up over 32% in six months on rate cut expectations and potential sector rotation. The State Street SPDR S&P Biotech ETF has surged 45% in six months but remains 27% ...
Stock exchange-traded funds, or equity ETFs, are often low-cost, tax-efficient instruments for investors to track popular indexes or leverage experienced manager choices to beat the market. The best ...
Building wealth isn’t about predicting the next Google or beating the market. It’s about growing a portfolio steadily and letting it compound over time. For most successful investors, the quiet ...
Exchange-traded funds are entering what could be their most transformative stretch yet and could mean a marketplace that looks markedly different by the end of the decade. Global ETF assets climbed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results